NCT06163170View on ClinicalTrials.gov

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

September 25, 2023

Study Completion Date

November 10, 2023

Conditions
Melanoma
Interventions
DRUG

Nivolumab +/- ipilimumab

Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma

DRUG

Nivolumab

Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma

Trial Locations (1)

43017

Cardinal Health, Dublin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06163170 - A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma | Biotech Hunter | Biotech Hunter